Cerus Co. (NASDAQ:CERS - Get Free Report) insider Richard J. Benjamin sold 18,949 shares of Cerus stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $1.45, for a total value of $27,476.05. Following the completion of the sale, the insider now directly owns 715,850 shares in the company, valued at approximately $1,037,982.50. This represents a 2.58 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.
Cerus Price Performance
Shares of Cerus stock opened at $1.45 on Tuesday. The business's 50 day simple moving average is $1.72 and its 200 day simple moving average is $1.75. Cerus Co. has a 52-week low of $1.38 and a 52-week high of $2.54. The firm has a market cap of $269.40 million, a PE ratio of -13.18 and a beta of 1.56. The company has a debt-to-equity ratio of 1.19, a quick ratio of 1.92 and a current ratio of 2.59.
Cerus (NASDAQ:CERS - Get Free Report) last posted its quarterly earnings results on Thursday, February 20th. The biotechnology company reported ($0.01) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.01). The firm had revenue of $50.81 million during the quarter, compared to the consensus estimate of $50.81 million. Cerus had a negative return on equity of 40.55% and a negative net margin of 11.60%. On average, analysts predict that Cerus Co. will post -0.08 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A number of hedge funds have recently bought and sold shares of the stock. Wealth Enhancement Advisory Services LLC bought a new position in Cerus in the fourth quarter valued at approximately $25,000. Squarepoint Ops LLC boosted its stake in shares of Cerus by 2,084.7% during the 4th quarter. Squarepoint Ops LLC now owns 492,732 shares of the biotechnology company's stock worth $759,000 after acquiring an additional 470,178 shares during the period. Two Sigma Advisers LP boosted its stake in shares of Cerus by 249.5% during the 4th quarter. Two Sigma Advisers LP now owns 254,100 shares of the biotechnology company's stock worth $391,000 after acquiring an additional 181,400 shares during the period. Two Sigma Investments LP boosted its stake in shares of Cerus by 121.6% during the 4th quarter. Two Sigma Investments LP now owns 595,234 shares of the biotechnology company's stock worth $917,000 after acquiring an additional 326,605 shares during the period. Finally, State of Wyoming boosted its stake in shares of Cerus by 39.1% during the 4th quarter. State of Wyoming now owns 129,840 shares of the biotechnology company's stock worth $200,000 after acquiring an additional 36,488 shares during the period. 78.37% of the stock is currently owned by institutional investors.
Wall Street Analysts Forecast Growth
Separately, Cantor Fitzgerald reissued an "overweight" rating and issued a $4.00 target price on shares of Cerus in a research report on Friday, February 21st.
View Our Latest Research Report on Cerus
Cerus Company Profile
(
Get Free Report)
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
